Takeda strengthens patient offering in India
Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based R&D-driven biopharmaceutical leader, announced the expansion of its highly innovative portfolio for patientsin the country with the launch of Kynteles®(generic name: Vedolizumab) as part of its Gastrointestinal (GI) portfolio.GI is Takeda’s second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology).[1]
Kynteles®is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD).Kynteles®, more widely known asEntvyio®, has shown favourablesafety and efficacy resultsin treatingpatients suffering from moderate to severeIBD[2],[3],[4].GI is Takeda’s second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology)The launch of our highly innovative GI portfolio is a testimony of our commitment to Indiaand patients living with diseases like UC and CD
Takeda strengthens patient offering in India
Speaking about the launch, Koki Sato, Country Head, Takeda India, said,”At Takeda, we are continuously working towards developing innovative medicinesto considerably improve the quality of life of patients. The launch of our highly innovative GI portfolio is a testimony of our commitment to Indiaand patients living with diseases like UC and CD. Patient access to Kynteles®will further augment our vision of providing additional and innovative treatment options to HCPs treating UC and CD.”Kynteles®is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD).Kynteles®, more widely known asEntvyio®, has shown favourablesafety and efficacy resultsin treatingpatients suffering from moderate to severeIBD[2],[3],[4].
Do Follow us on :- Facebook, Instagram, Twitter
